Investigation of the effect of GLP-1 and left ventricular function during myocardial ischaemia
| ISRCTN | ISRCTN69686930 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN69686930 |
| Protocol serial number | 6562 |
| Sponsor | Cambridge University Hospitals NHS Foundation Trust (UK) |
| Funder | Medical Research Council (MRC) (UK) |
- Submission date
- 19/05/2010
- Registration date
- 19/05/2010
- Last edited
- 11/08/2015
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Davis Dutka
Scientific
Scientific
University of Cambridge
Addenbrookes Hospital
Hills Road
Cambridge
CB2 2QQ
United Kingdom
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Single-centre non-randomised interventional treatment trial |
| Secondary study design | Non randomised study |
| Scientific title | Investigation of the effect of GLP-1 and left ventricular function during myocardial ischaemia |
| Study acronym | GLP-1 and left ventricular function during ischaemia |
| Study objectives | The hypothesis is that infusion of glucagon-like peptide-1 will protect the heart from ischaemia and improve left ventricular (LV) function during dobutamine stress echocardiography in patients with coronary artery disease |
| Ethics approval(s) | MREC approved, ref: 08/H0304/68 |
| Health condition(s) or problem(s) studied | Topic: Cardiovascular; Subtopic: Cardiovascular (all Subtopics); Disease: Cardiovascular |
| Intervention | In the active DSE, patients will receive an infusion of GLP-1 intravenously at 1.2 pmol/kg/min starting 30 minutes prior to the DSE and continuing for 30 minutes into recovery. In the control scan there will be no infusion. |
| Intervention type | Drug |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Glucagon-like peptide-1 |
| Primary outcome measure(s) |
Global LV function at peak stress |
| Key secondary outcome measure(s) |
1. Global LV function at 30 minutes recovery |
| Completion date | 30/07/2010 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Target sample size at registration | 30 |
| Key inclusion criteria | Not provided at time of registration |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 17/06/2009 |
| Date of final enrolment | 30/07/2010 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
University of Cambridge
Cambridge
CB2 2QQ
United Kingdom
CB2 2QQ
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/03/2012 | Yes | No | |
| Results article | results | 08/08/2015 | Yes | No |
